Motif Bio Reports Year-End 2016 Financial Results
NEW YORK, May 01, 2017 (GLOBE NEWSWIRE) -- Motif Bio plc (NASDAQ:MTFB) (AIM:MTFB.LN), a clinical stage biopharmaceutical company specialising in developing novel antibiotics, today announced financial results for the year ended December 31, 2016.
"Motif Bio made significant progress in 2016 towards our goal of bringing our novel antibiotic candidate, iclaprim, to patients with serious and life-threatening infections. The announcement of positive Phase 3 topline results for iclaprim in REVIVE-1 was a major achievement for Motif Bio and we expect to announce the topline data from REVIVE-2, the second Phase 3 trial, in the second half of 2017," commented Graham Lumsden, CEO of Motif Bio plc.
Recent Corporate Developments
- Announced positive topline results for iclaprim in the REVIVE-1 Phase 3 study of acute bacterial skin and skin structure infections (ABSSSI)
- Data from REVIVE-2, which uses an identical protocol to REVIVE-1 but has different trial centres, has more than 80% of the total patients enrolled, and data is expected in the second half of 2017
- Achieved a NASDAQ listing
- Closed a U.S. initial public offering and a concurrent European placement with aggregate net proceeds of $21.5 million, which brought the total raised by the Company to approximately $65 million
- Appointed Robert Dickey IV as Chief Financial Officer
- Presented two posters at ID Week 2016. The first showed new data demonstrating that iclaprim is highly potent in vitro against bacterial strains associated with clinical Hospital Associated Bacterial Pneumonia (HABP) and Skin and Skin Structure Infections (SSSI) clinical isolates. The second poster described the potential benefits of an optimized 80mg fixed dose of iclaprim administered intravenously over 120 minutes, that is being used in the REVIVE Phase 3 clinical trials. Improvement by approximately 30% in the PK/PD parameters associated with efficacy, AUC/MIC and t/MIC, was seen compared to the previously studied weight based dose of 0.8 mg/kg.
- Completed preparations for INSPIRE, a Phase 3 trial designed to study the safety and efficacy of iclaprim in patients with HABP, including ventilator associated bacterial pneumonia (VABP)
- Completed additional research with clinicians and payers to understand how iclaprim may be able to address the unmet need in hospitalised ABSSSI patients with renal impairment with/without diabetes
Full Year 2016 Financial Results
- For the full year, Motif Bio reported a net loss of $40.3 million, or $(0.35) per share (basic and diluted) compared to a net loss of $8.5 million, or $(0.14) per share (basic and diluted) during the same period in 2015.
- Research and development (R&D) costs for 2016 were $34.8 million compared to $4.7 million during 2015. Higher R&D costs in 2016 were primarily attributable to the commencement of iclaprim clinical development. Clinical development expenses are a significant component of our research and development expenses and product candidates in later stage development generally have higher costs.
- General and administrative expenses for 2016 were $4.9 million compared to $3.6 million during 2015. The increase is primarily due to the costs associated with the filing of a registration statement relating to the initial public offering in the U.S.; costs associated with being a public company in both the United Kingdom and the U.S.; and increases in the costs of outside professional services.
- Cash and cash equivalents were $21.8 million as of December 31, 2016.
- As of December 31, 2016, the Company had 195.7 million ordinary shares outstanding.
Motif Bio has filed its U.S. Annual Report on Form 20-F for the year ended December 31, 2016 with the US Securities and Exchange Commission ("SEC"). The Form 20-F is available to download, either from the Investors section of the Company website at www.motifbio.com, the SEC website at www.sec.gov or from the link below.
Click here to download the Form 20-F
Iclaprim is a potential novel antibiotic, designed to be effective against bacteria that have developed resistance to other antibiotics, including trimethoprim. Iclaprim exhibits potent in vitro activity against Gram-positive clinical isolates of many genera of staphylococci, including methicillin sensitive Staphylococcus aureus (MSSA) and methicillin resistant Staphylococcus aureus (MRSA). The MIC90 of iclaprim was lower than most comparators including vancomycin and linezolid, standard of care therapies used in serious and life-threatening Gram-positive hospital infections. To date, iclaprim has been studied in over 1,000 patients and healthy volunteers. Iclaprim is administered intravenously at a fixed dose, with no dosage adjustment required in patients with renal impairment, or in obese patients. This may help reduce overall hospital treatment costs, especially in renally impaired patients.
About Motif Bio plc www.motifbio.com Motif Bio is a clinical-stage biopharmaceutical company, engaged in the research and development of novel antibiotics designed to be effective against serious and life-threatening infections in hospitalised patients caused by multi-drug resistant bacteria. Our lead product candidate, iclaprim, is being developed for the treatment of acute bacterial skin and skin structure infections (ABSSSI) and hospital acquired bacterial pneumonia (HABP), including ventilator associated bacterial pneumonia (VABP), infections often caused by MRSA (methicillin resistant Staphylococcus aureus). Having completed the REVIVE-1 trial, patients are currently being enrolled and dosed in a second global Phase 3 clinical trial (REVIVE-2) with an intravenous formulation of iclaprim, for the treatment of ABSSSI. Data readout for REVIVE-2 is expected in the second half of 2017.
This press release contains forward-looking statements. Words such as "expect," "believe," "intend," "plan," "continue," "may," "will," "anticipate," and similar expressions are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that may cause Motif Bio's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Motif Bio believes that these factors include, but are not limited to, (i) the timing, progress and the results of clinical trials for Motif Bio's product candidates, (ii) the timing, scope or likelihood of regulatory filings and approvals for Motif Bio's product candidates, (iii) Motif Bio's ability to successfully commercialize its product candidates, (iv) Motif Bio's ability to effectively market any product candidates that receive regulatory approval, (v) Motif Bio's commercialisation, marketing and manufacturing capabilities and strategy, (vi) Motif Bio's expectation regarding the safety and efficacy of its product candidates, (vii) the potential clinical utility and benefits of Motif Bio's product candidates, (viii) Motif Bio's ability to advance its product candidates through various stages of development, especially through pivotal safety and efficacy trials, and (ix) Motif Bio's estimates regarding the potential market opportunity for its product candidates, and (x) the factors discussed in the section entitled "Risk Factors" in Motif Bio plc's Annual Report on Form 20-F filed with the SEC on May 1, 2017, which is available on the SEC's web site, www.sec.gov. Motif Bio plc undertakes no obligation to update or revise any forward-looking statements.
"This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No 596/2014 and has been released by Robert Dickey IV, Chief Financial Officer, on behalf of the Company."
For further information please contact:
|Motif Bio email@example.com|
|Graham Lumsden (Chief Executive Officer)|
|Robert Dickey IV (Chief Financial Officer)|
|Peel Hunt LLP (NOMAD & BROKER)||+ 44 (0)20 7418 8900|
|Dr Christopher Golden|
|Northland Capital Partners Limited (BROKER)||+44 (0)203 861 6625|
|Patrick Claridge/ David Hignell|
|John Howes/ Rob Rees (Broking)|
|Westwicke Partners||001 415-513-1284|
|Patricia L. Bankfirstname.lastname@example.org|
|Walbrook PR Ltd. (FINANCIAL PR & IR)||+44 (0) 20 7933 8780 or email@example.com|
|Paul McManus||Mob: +44 (0)7980 541 893|
|Mike Wort||Mob: +44 (0)7900 608 002|
|MC Services AG (EUROPEAN IR)||+49 (0)89 210 2280|
Motif Bio plc Selected Financial Data
|General and administrative expenses||(4,912,150||)||(3,577,180||)||(1,096,116||)|
|Research and development expenses||(34,794,815||)||(4,680,940||)||-|
|Gains on settlement of contract disputes||83,320||5,027||360,060|
|Net foreign exchange losses||(250,926||)||(9,644||)||-|
|Loss from revaluation of derivative liabilities||(135,939||)||-||-|
|Loss before income taxes||(40,324,015||)||(8,515,925||)||(1,185,014||)|
|Net loss for the year||(40,324,302||)||(8,516,699||)||(1,185,890||)|
|Total comprehensive loss for the year||(40,324,302||)||(8,516,699||)||(1,185,890||)|
|Net loss per share|
|Basic and diluted per share *||$||(0.35||)||$||(0.14||)||$||(0.03||)|
|Weighted average number of ordinary shares, basic and diluted||116,558,191||61,225,922||36,726,342|
|* In accordance with IAS 33 "Earnings per share", shares are not diluted where the entity has reported a loss for the period.|
|December 31, 2016||December 31, 2015|
|US $||US $|
|Total non-current assets||6,195,748||6,195,748|
|Prepaid expenses and other receivables||401,064||167,657|
|Total current assets||22,230,696||28,762,004|
|Payable on completion of clinical trial||-||500,000|
|Total non-current liabilities||-||500,000|
|Trade and other payables||12,319,117||987,083|
|Other interest-bearing loans and borrowings||-||3,747,961|
|Payable on completion of clinical trial||500,000||-|
|Total current liabilities||18,617,175||4,735,044|
|Group reorganization reserve||9,938,362||9,938,362|
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Motif BioSciences Inc. via Globenewswire
Följ NASDAQ OMX
Skriv in din e-postadress så får du ett mejl när vi har något nytt att berätta.
Senaste pressmeddelandena från NASDAQ OMX
Hitachi Vantara Unveils New Turnkey IoT Appliance, Powered by Lumada Software19.9.2017 17:50 | Pressmeddelande
Hitachi IoT Appliance Accelerates the Time to Insight and Value of IoT Solution Deployments for Industrial and Commercial Enterprise Customers LAS VEGAS, Sept. 19, 2017 (GLOBE NEWSWIRE) -- Hitachi Vantara, a wholly owned subsidiary of Hitachi, Ltd. (TSE:6501), today unveiled a new appliance for internet of things (IoT) deployments: Hitachi IoT Appliance, powered by Lumada, Hitachi's IoT platform. Delivered as a turnkey system, the appliance's "hyperconverged meets microservices" architecture combines Hitachi's best-in-class storage and compute with industry-leading networking technologies and comes fully integrated with Hitachi's latest Lumada software. Hitachi IoT Appliance has been fully pre-architected and pre-validated to provide a plug-and-play solution that can be easily deployed and production-ready in under an hour. This gives users the ability to more rapidly connect, monitor and extract actionable insights from their business and industrial assets. Fo
Hitachi Aims To Disrupt Industrial IoT Platform Market With New Commercial Lumada Software Stack19.9.2017 17:50 | Pressmeddelande
Fully Enhanced and Now Available as a Standalone Offering for IoT Developers and Architects, Hitachi's Lumada Provides an Intelligent, Composable Platform That Delivers Faster Time to Insight and Business Value for Industrial and Enterprise Customers TOKYO and LAS VEGAS, Sept. 19, 2017 (GLOBE NEWSWIRE) -- Hitachi Ltd. (TSE:6501) and Hitachi Vantara, today jointly announced Hitachi's first commercial Lumada internet of things (IoT) platform offering. Now in its v2.0 release, the Lumada IoT platform has been fully updated with an elegant, portable architecture that enables it to run both on-premises or in the cloud and to support industrial IoT deployments both at the edge and in the core. The new software stack is designed to help customers quickly and easily gain insights, predictions and recommendations from their data, and can be easily adapted to support mid-to-large-scale environments. Lumada's integrated advanced analytics have also b
Hitachi Introduces Hitachi Vantara: A New Digital Company Committed to Solving the World's Toughest Business and Societal Challenges19.9.2017 17:45 | Pressmeddelande
Company Formed to Help Customers Achieve Unprecedented Outcomes by Tapping the Full Potential of Their Data TOKYO and LAS VEGAS, Sept. 19, 2017 (GLOBE NEWSWIRE) -- Hitachi, Ltd. (TSE:6501) ("Hitachi") today launched Hitachi Vantara, a new business entity to leverage the broad portfolio of innovation, development and experience from across Hitachi Group companies to deliver data-driven solutions for commercial and industrial enterprises. This new company will unify the operations of Hitachi Data Systems, Hitachi Insight Group, and Pentaho into a single integrated business as Hitachi Vantara to capitalize on Hitachi's social innovation capability in both operational technologies (OT) and information technologies (IT). More Than a Century of OT Expertise Combined with IT Trusted by the World's Largest Enterprises Hitachi has been a leader in OT for industries such as finance, government, manufacturing, power/energy and transportation
Sigma Designs Launches Z-Wave Smart Home Maker Challenge19.9.2017 17:00 | Pressmeddelande
Sigma Designs and Make: Debut Smart Home Design Mission at World Maker Faire 2017 in New York Celebrating Maker Community Creativity, Collaboration and Inspiring Z-Wave App Design FREMONT, Calif., Sept. 19, 2017 (GLOBE NEWSWIRE) -- Sigma Designs® (NASDAQ:SIGM), a leading provider of intelligent system-on-chip (SoC) solutions for Connected Smart TV platforms and Smart home IoT, and Make:, leader of the Maker movement and producer of the popular Maker Faire events, today announces a smart home Z-Wave app design contest for Makers and Developers. Sigma Designs launches the Z-Wave Smart Home Maker Challenge today in cooperation with Make: and in unison with the flag-ship World Maker Faire that takes place in New York City September 23-24th. The smart home design competition will be hosted on the all-new Maker Share community platform where participants will have the opportunity to submit their idea for a smart home application that would turn their dream sm
3Gtms Names Managing Director of EMEA19.9.2017 16:00 | Pressmeddelande
Chris van der Harst will lead growth of unique TMS solution SHELTON, Conn., Sept. 19, 2017 (GLOBE NEWSWIRE) -- 3Gtms, Inc., a global provider of Tier 1 transportation management software (TMS), announced that it has named Chris van der Harst to the new position of managing director, EMEA. In this position, van der Harst will lead 3Gtms' overseas efforts from its EMEA headquarters in Utrecht, The Netherlands. He will be responsible for growing 3Gtms' market share among 3PLs and mid-large sized shippers, as well as ensuring 3Gtms' industry-leading satisfaction rate is upheld among all customers. 3Gtms' robust TMS gives 3PLs and shippers the most powerful and intuitive system for over-the-road and intermodal freight, along with best-in-class rating and optimization. The modern design enables flexible, seamless handling of the most complicated shipping requirements, covering the complete order-to-cash process. A 30-year supply cha
Novavax Initiates Phase 1/2 Trial of NanoFlu(TM) Vaccine in Older Adults19.9.2017 15:05 | Pressmeddelande
Recently published NanoFlu(TM) preclinical data provide strong rationale for Phase 1/2 clinical trial based on robust antibody titers and improved protective responses against both current and drifted strains Data from trial expected by the end of 2017 GAITHERSBURG, Md., Sept. 19, 2017 (GLOBE NEWSWIRE) -- Novavax, Inc., (Nasdaq:NVAX) today announced the enrollment of the first participant in a Phase 1/2 clinical trial of its nanoparticle influenza vaccine candidate including its proprietary Matrix-M(TM) adjuvant (NanoFlu(TM)) in older adults. The trial is a randomized, observer-blinded, active comparator-controlled trial in approximately 330 healthy older adults. The primary objective of the trial is to assess the safety and immunogenicity of two concentrations (15 µg or 60 µg) of NanoFlu compared to a licensed influenza vaccine, Fluzone® High-Dose (Fluzone HD).
I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.Besök vårt pressrum